01—Abstract
Summary
Summary of the 8-K filed November 3, 2025. Cited figures are marked; the original filing is the authoritative source.
On November 3, 2025, Omega Healthcare Investors, Inc. entered into a new at-the-market (ATM) equity offering sales agreement with a broad group of sales agents, forward sellers and forward purchasers.
The agreement covers the issuance and sale of shares of its common stock, par value $0.10a per share, together with forward shares, with aggregate gross sales not to exceed $2,000,000,000. On the same date, the company terminated its prior at-the-market equity offering sales agreement dated September 6, 2024. The company has no obligation to sell any securities under the agreement and may suspend offers at any time.
Sales, if any, may occur on the New York Stock Exchange, in negotiated transactions, or by other methods permitted by law. Each sales agent's compensation will not exceed 2.0%b of the gross sales price of shares it sells as agent, and forward sellers' commissions will not exceed 2.0% of the gross sales price of borrowed shares sold, paid through a reduced initial forward sale price. Under forward sale agreements, the company expects to physically settle by delivering shares and receiving proceeds no later than two years after entry into each agreement, but it may instead elect cash or net share settlement, in which case it may receive no proceeds.
The securities are being offered under an automatic shelf registration statement on Form S-3 (No. 333-277916) and a prospectus supplement dated November 3, 2025. Several of the agents and their affiliates have provided and may continue to provide banking and advisory services to the company for customary fees.
02—Key points
Key Highlights
- Entered a new at-the-market equity sales agreement on November 3, 2025, covering up to $2,000,000,000 in aggregate gross sales of common stock and forward shares
- Terminated the prior at-the-market equity offering sales agreement dated September 6, 2024, on the same date
- Sales agents may receive compensation of up to 2.0% of the gross sales price of shares sold through them as agent
- Forward sellers' commissions are capped at 2.0% of the gross sales price of borrowed shares and are paid via a reduced initial forward sale price
- The company expects to physically settle forward sale agreements within two years but may elect cash or net share settlement, which could mean no proceeds received
- No obligation to sell any securities; the company may suspend offerings at any time
- Offering is made under automatic shelf registration statement on Form S-3 (No. 333-277916) with a prospectus supplement dated November 3, 2025
03—Questions
Frequently Asked Questions
How large is the new at-the-market equity program?
The securities sold under the Sales Agreement may not exceed an aggregate gross sales price of $2,000,000,000.
Is Omega Healthcare Investors required to sell shares under this agreement?
No. The company has no obligation to sell any of the securities under the Sales Agreement and may suspend solicitations and offers at any time.
How will the company receive proceeds from forward sale agreements?
The company expects to physically settle forward sale agreements by delivering common stock and receiving proceeds no later than two years after entering each agreement. It may instead elect cash settlement or net share settlement, in which case it may receive no proceeds and may owe cash or shares to the forward purchaser in certain circumstances.
What compensation do the sales agents and forward sellers receive?
Sales agents are entitled to compensation not exceeding 2.0% of the gross sales price of Issuance Shares sold through them as agent. Forward sellers are entitled to commissions at a mutually agreed rate not exceeding 2.0% of the gross sales price of borrowed shares sold, paid through a reduced initial forward sale price.
What happened to the company's prior at-the-market program?
On November 3, 2025, the company terminated its prior at-the-market equity offering sales agreement dated September 6, 2024, and replaced it with the new Sales Agreement.
04—Continue